Designing a patent family strategy in life sciences requires more than prosecution. This article explains how U.S. continuation practice can be structured as patent family architecture, aligned to biotech and pharmaceutical regulatory milestones, valuation strategy, licensing, and commercialization, while strengthening patent portfolio risk mitigation.

Intellectual property is the foundation of biotech success. Discover how platform-driven IP strategies, licensing frameworks, and strategic collaborations can amplify valuation, attract investors, and accelerate commercialization. Learn how Hylton Rodic Law helps biotech innovators protect the science, structure the deal, and scale the business.

AI can accelerate innovation, but it can also introduce synthetic prior art that undermines biotech IP. Explore key risks in operability, public access, and misuse. Learn how to protect your patent filings with expert strategies.